poultry farming business plan write an essay on personality homework practice workbook algebra 1 answers help on science homework writing a introduction for a essay help writing papers for high school
Skip to main content

TMEM16A inhibitors as a treatment option for cystic fibrosis

Ref-Nr: TA-B78025


Kurzfassung

  • TMEM16A inhibitors represent a causal treatment for cystic fibrosis
  • They reduce both excessive mucus formation and airway contraction
  • Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs

Hintergrund

It is estimated that more than 70 000 patients worldwide are suffering from cystic fibrosis (CF), a lethal genetic disorder characterized by a severe pulmonary disease caused by production a highly viscous and adherent mucus. Because CF is caused by more than 2000 different mutations, a therapy from which all patients would benefit does not exist. An ideal causal therapy for CF would reduce the excessive mucus formation as well as the airway contraction.


Bilder & Videos


Lösung

Both can be achieved by using compounds that inhibit the calcium-activated chloride channel TMEM16A, which plays a crucial role in both airway smooth muscle contraction and mucus formation. Among such compounds, the FDA-approved and well-tolerated drug niclosamide and related substances have been shown to effectively reduce mucus formation in preclinical animal studies. The drugs may ideally be formulated for inhaled delivery with a spray or nebulizer.


Anwendungsbereiche

  • TMEM16A inhibitors reduce axcessive mucus production as well as airway contraction
  • Possible repurposing of FDA-proven and well-tolerated drugs
  • Development of a drug formulation for inhalation (in form of a spray or nebulizer)

Bayerische Patentallianz GmbH


089 5480177-0
kontakt@baypat.de
www.baypat.de
Adresse
Destouchesstr. 68
80796 München



Entwicklungsstand

Klinischer Funktionsnachweis


Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen